CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531

PURPOSE: CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet limited data exist about whether GO response correlates with CD33 expression level. PATIENTS AND METHODS: CD33 ex...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Pollard, Jessica A., Loken, Michael, Gerbing, Robert B., Raimondi, Susana C., Hirsch, Betsy A., Aplenc, Richard, Bernstein, Irwin D., Gamis, Alan S., Alonzo, Todd A., Meshinchi, Soheil
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2016
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872025/
https://ncbi.nlm.nih.gov/pubmed/26786921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.6846
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg